PortalPublikationenDecay-accelerating factor (CD55): a versatile acting molecul...

Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies.

Standard

Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. / Mikesch, Jan-Henrik; Buerger, Horst; Simon, Ronald; Brandt, Burkhard.

in: BBA-BIOMEMBRANES, Jahrgang 1766, Nr. 1, 1, 2006, S. 42-52.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Mikesch, J-H, Buerger, H, Simon, R & Brandt, B 2006, 'Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies.', BBA-BIOMEMBRANES, Jg. 1766, Nr. 1, 1, S. 42-52. <http://www.ncbi.nlm.nih.gov/pubmed/16784816?dopt=Citation>

APA

Mikesch, J-H., Buerger, H., Simon, R., & Brandt, B. (2006). Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. BBA-BIOMEMBRANES, 1766(1), 42-52. [1]. http://www.ncbi.nlm.nih.gov/pubmed/16784816?dopt=Citation

Vancouver

Mikesch J-H, Buerger H, Simon R, Brandt B. Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. BBA-BIOMEMBRANES. 2006;1766(1):42-52. 1.

Bibtex

@article{6ae952466dc4447093bc27b997e760b1,
title = "Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies.",
abstract = "The decay-accelerating factor (DAF, CD55) physiologically serves as an inhibitor of the complement system. Moreover, DAF is broadly expressed in malignant tumors. Here, DAF seems to dispose of several different functions reaching far beyond its immunological role, e.g., promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathway activation, and specific seven-span transmembrane receptors (CD97) binding. Furthermore, DAF has already been included in diagnostic or therapeutic studies. Thereby, studies applying monoclonal anti-DAF antibodies and anti-DAF vaccination for a targeted therapy have been enrolled recently.",
author = "Jan-Henrik Mikesch and Horst Buerger and Ronald Simon and Burkhard Brandt",
year = "2006",
language = "Deutsch",
volume = "1766",
pages = "42--52",
journal = "BBA-BIOMEMBRANES",
issn = "0005-2736",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies.

AU - Mikesch, Jan-Henrik

AU - Buerger, Horst

AU - Simon, Ronald

AU - Brandt, Burkhard

PY - 2006

Y1 - 2006

N2 - The decay-accelerating factor (DAF, CD55) physiologically serves as an inhibitor of the complement system. Moreover, DAF is broadly expressed in malignant tumors. Here, DAF seems to dispose of several different functions reaching far beyond its immunological role, e.g., promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathway activation, and specific seven-span transmembrane receptors (CD97) binding. Furthermore, DAF has already been included in diagnostic or therapeutic studies. Thereby, studies applying monoclonal anti-DAF antibodies and anti-DAF vaccination for a targeted therapy have been enrolled recently.

AB - The decay-accelerating factor (DAF, CD55) physiologically serves as an inhibitor of the complement system. Moreover, DAF is broadly expressed in malignant tumors. Here, DAF seems to dispose of several different functions reaching far beyond its immunological role, e.g., promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathway activation, and specific seven-span transmembrane receptors (CD97) binding. Furthermore, DAF has already been included in diagnostic or therapeutic studies. Thereby, studies applying monoclonal anti-DAF antibodies and anti-DAF vaccination for a targeted therapy have been enrolled recently.

M3 - SCORING: Zeitschriftenaufsatz

VL - 1766

SP - 42

EP - 52

JO - BBA-BIOMEMBRANES

JF - BBA-BIOMEMBRANES

SN - 0005-2736

IS - 1

M1 - 1

ER -